Catalyst Pharmaceuticals, Inc. (CPRX) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Coral Gables, FL, United States. Le PDG actuel est Richard John Daly.
CPRX a date d'introduction en bourse 2006-11-08, 181 employés à temps plein, cotée sur le NASDAQ Capital Marke, une capitalisation boursière de $3.22B.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company headquartered in Coral Gables, Florida, specializing in therapies for rare neuromuscular and neurological diseases. The company's primary product, Firdapse (amifampridine phosphate), is approved for treating Lambert-Eaton Myasthenic Syndrome (LEMS) in adults, while its pediatric formulation, Ruzurgi, addresses LEMS in children. Catalyst is advancing Firdapse through clinical development for additional indications including MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company maintains strategic partnerships with BioMarin Pharmaceutical Inc. and Endo Ventures Limited for product development and commercialization efforts.
